Por favor, use este identificador para citar o enlazar este ítem:
https://doi.org/10.1111/eci.13050
Twittear
Título: | Increasing Therapy Related Myeloid Neoplasms in Multiple Myeloma |
Fecha de publicación: | 13-nov-2018 |
Editorial: | Wiley |
Cita bibliográfica: | European Journal of Clinical InvestigationVolume 49, Issue 2 e13050 |
ISSN: | Electronic: 1365-2362 Print: 0014-2972 |
Palabras clave: | Complex karyotype Multiple myeloma Myelodysplastic syndrome |
Resumen: | Background: Despite the longer survival achieved in multiple myeloma (MM) patients due to new therapy strategies, a concern is emerging regarding an increased risk of secondary primary malignancies (SPMs) and how to characterize those patients at risk. We performed a retrospective study covering a 28‐year follow‐ up period (1991‐2018) in a tertiary single institution. Material and Methods: Data of 403 MM patients were recorded and compared with the epidemiologic register of the population area covered by our centre, calculating the standardize incidence ratio (SIR) for the different types of SPMs diagnosed in the MM cohort. Fine and Gray regression models were used to identify risk factors for SPMs. Results: Out of the 403 MM patients, 23 (5.7%) developed SPMs: 13 therapyrelated myeloid (TRM) malignancies (10 of them (77%) myelodysplastic syndrome (MDS), 1 acute lymphoid leukaemia and 9 solid neoplasms. In the MM cohort, the relative risk of MDS was significantly higher than in the general population. Survival of patients with TRM malignancies was poor with a median of 4 months from the diagnosis, and most of them showed complex karyotype. Within the MM subset, multivariable analysis showed a higher risk of TRM malignancies in patients that previously received prolonged treatment with lenalidomide (>18 months). Conclusions: Though the improvement in MM outcome during the last decades is an unprecedented achievement, it has been accompanied by the rise in TRM malignancies with complex cytogenetic profile and poor prognosis that are in the need of an improved biologic and therapeutic approach. |
Autor/es principal/es: | Fernández-Caballero, M Salmerón, D Chirlaque, MD Chen-Liang, TH Hurtado, AM García Malo, MD Ortuño, FJ Roldán, V Vicente, V Jerez, A De Arriba, F |
Facultad/Departamentos/Servicios: | Facultades, Departamentos, Servicios y Escuelas::Departamentos de la UMU::Ciencias Sociosanitarias |
Versión del editor: | https://onlinelibrary.wiley.com/doi/10.1111/eci.13050 |
URI: | http://hdl.handle.net/10201/137251 |
DOI: | https://doi.org/10.1111/eci.13050 |
Tipo de documento: | info:eu-repo/semantics/article |
Número páginas / Extensión: | 8 |
Derechos: | info:eu-repo/semantics/openAccess Atribución-NoComercial 4.0 Internacional |
Descripción: | © 2018 Stichting European Society for Clinical Investigation Journal Foundation. This document is made available under the CC-BY-NC 4.0 license http://creativecommons.org/licenses/by-nc /4.0/ This document is the submitted version of a published work that appeared in final form in European Journal of Clinical Investigation. |
Aparece en las colecciones: | Artículos: Ciencias Sociosanitarias |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
SegundaNeo_2019_deposito.pdf | 174,2 kB | Adobe PDF | Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons